Sidenafil pre-treatment promotes decompression sickness in rats.

Vascular bubble formation after decompression contributes to endothelial injuries which form the basis for the development of decompression sickness (DCS). Nitric oxide (NO) is a powerful vasodilator that contributes to vessel homeostasis. It has been shown that NO-releasing agent may reduce bubble...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jean-Eric Blatteau, Alf O Brubakk, Emmanuel Gempp, Olivier Castagna, Jean-Jacques Risso, Nicolas Vallée
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/b856fe960beb4391a2f5470bb99c2949
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b856fe960beb4391a2f5470bb99c2949
record_format	dspace
spelling	oai:doaj.org-article:b856fe960beb4391a2f5470bb99c29492021-11-18T07:50:14ZSidenafil pre-treatment promotes decompression sickness in rats.1932-620310.1371/journal.pone.0060639https://doaj.org/article/b856fe960beb4391a2f5470bb99c29492013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23580342/?tool=EBIhttps://doaj.org/toc/1932-6203Vascular bubble formation after decompression contributes to endothelial injuries which form the basis for the development of decompression sickness (DCS). Nitric oxide (NO) is a powerful vasodilator that contributes to vessel homeostasis. It has been shown that NO-releasing agent may reduce bubble formation and prevent serious decompression sickness. The use of sildenafil, a well-known, phosphodiesterase-5 blocker, which act by potentiating the vasodilatory effect on smooth muscle relaxation, has never been studied in DCS. The purpose of the present study was to evaluate the clinical effects of sildenafil pre-treatment on DCS in a rat model. 67 rats were subjected to a simulated dive at 90 msw for 45 min before staged decompression. The experimental group received 10 mg/kg of sildenafil one hour before exposure (n = 35) while controls were not treated (n = 32). Clinical assessment took place over a period of 30 min after surfacing. At the end, blood samples were collected for blood cells counts and the level of circulating bubbles in the right cavities was quantified. There were significantly more manifestations of DCS in the sildenafil group than in the controls (34.3% vs 6.25%, respectively, p = 0.012). Platelet count was more reduced in treated rats than in controls (-21.7% vs -7%, respectively, p = 0.029), whereas bubble grades did not differ between groups. We concluded that pre-treatment with sildenafil promotes the onset and severity of neurological DCS. When considering the use of phosphodiesterase-5 blockers in the context of diving, careful discussion with physician should be recommended.Jean-Eric BlatteauAlf O BrubakkEmmanuel GemppOlivier CastagnaJean-Jacques RissoNicolas ValléePublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 4, p e60639 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jean-Eric Blatteau Alf O Brubakk Emmanuel Gempp Olivier Castagna Jean-Jacques Risso Nicolas Vallée Sidenafil pre-treatment promotes decompression sickness in rats.
description	Vascular bubble formation after decompression contributes to endothelial injuries which form the basis for the development of decompression sickness (DCS). Nitric oxide (NO) is a powerful vasodilator that contributes to vessel homeostasis. It has been shown that NO-releasing agent may reduce bubble formation and prevent serious decompression sickness. The use of sildenafil, a well-known, phosphodiesterase-5 blocker, which act by potentiating the vasodilatory effect on smooth muscle relaxation, has never been studied in DCS. The purpose of the present study was to evaluate the clinical effects of sildenafil pre-treatment on DCS in a rat model. 67 rats were subjected to a simulated dive at 90 msw for 45 min before staged decompression. The experimental group received 10 mg/kg of sildenafil one hour before exposure (n = 35) while controls were not treated (n = 32). Clinical assessment took place over a period of 30 min after surfacing. At the end, blood samples were collected for blood cells counts and the level of circulating bubbles in the right cavities was quantified. There were significantly more manifestations of DCS in the sildenafil group than in the controls (34.3% vs 6.25%, respectively, p = 0.012). Platelet count was more reduced in treated rats than in controls (-21.7% vs -7%, respectively, p = 0.029), whereas bubble grades did not differ between groups. We concluded that pre-treatment with sildenafil promotes the onset and severity of neurological DCS. When considering the use of phosphodiesterase-5 blockers in the context of diving, careful discussion with physician should be recommended.
format	article
author	Jean-Eric Blatteau Alf O Brubakk Emmanuel Gempp Olivier Castagna Jean-Jacques Risso Nicolas Vallée
author_facet	Jean-Eric Blatteau Alf O Brubakk Emmanuel Gempp Olivier Castagna Jean-Jacques Risso Nicolas Vallée
author_sort	Jean-Eric Blatteau
title	Sidenafil pre-treatment promotes decompression sickness in rats.
title_short	Sidenafil pre-treatment promotes decompression sickness in rats.
title_full	Sidenafil pre-treatment promotes decompression sickness in rats.
title_fullStr	Sidenafil pre-treatment promotes decompression sickness in rats.
title_full_unstemmed	Sidenafil pre-treatment promotes decompression sickness in rats.
title_sort	sidenafil pre-treatment promotes decompression sickness in rats.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/b856fe960beb4391a2f5470bb99c2949
work_keys_str_mv	AT jeanericblatteau sidenafilpretreatmentpromotesdecompressionsicknessinrats AT alfobrubakk sidenafilpretreatmentpromotesdecompressionsicknessinrats AT emmanuelgempp sidenafilpretreatmentpromotesdecompressionsicknessinrats AT oliviercastagna sidenafilpretreatmentpromotesdecompressionsicknessinrats AT jeanjacquesrisso sidenafilpretreatmentpromotesdecompressionsicknessinrats AT nicolasvallee sidenafilpretreatmentpromotesdecompressionsicknessinrats
_version_	1718422876235759616

Sidenafil pre-treatment promotes decompression sickness in rats.

Ejemplares similares